Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation
| Autor: | Musa Baris Aykan, Halil Kizilöz, Galip Buyukturan, Gokhan Erdem, Ramazan Esen, Ramazan Acar, Yuksel Urun, Fikret Arpaci, Ismail Erturk, Birol Yildiz, Nuri Karadurmus |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Transplantation
Autologous Carboplatin 03 medical and health sciences High dose chemotherapy chemistry.chemical_compound 0302 clinical medicine Refractory Antineoplastic Combined Chemotherapy Protocols Medicine Humans Pharmacology (medical) Etoposide Retrospective Studies business.industry Hematopoietic Stem Cell Transplantation Neoplasms Germ Cell and Embryonal Combined Modality Therapy Transplantation Haematopoiesis medicine.anatomical_structure Oncology chemistry 030220 oncology & carcinogenesis Cancer research Stem cell business Germ cell 030215 immunology medicine.drug |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(7) |
| ISSN: | 1477-092X |
| Popis: | Introduction and aim To demonstrate the real-life data about patients who underwent AHSCT due to GCT. Methods Between November 2016 and April 2020, 64 patients who received CE as high-dose chemotherapy for AHSCT in the Gulhane Education and Research Hospital were included in the study. Sixty-one patients received one AHSCT with CE chemotherapy regimen. Survival data and clinical characteristics were evaluated retrospectively. Results The mean age of the patients were 31.9 ± 9 (min-max:18–55). With a median follow-up of 10.7 ± 8.7 months, the 1-year progression-free survival (PFS) rate was 57.8%, and the 1-year overall survival rate was 77.5%. Median overall survival (OS) and progression-free survival (PFS) times were 21.5 ± 1.8 (95% CI: 14.5–33.4) and 20 ± 2 months, respectively. The response rate was 72%. There were three treatment-related deaths. Conclusion This sizeable single-centre study shows that patients with relapsed metastatic GCT are curable by CE as high dose chemotherapy plus AHSCT with reliable toxicity even for a single cycle. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|